Viridian Therapeutics VRDN has announced detailed plans for a late-stage program on VRDN-003, its investigational subcutaneously (SC)-administered antibody, in patients with moderate-to-severe thyroid...
Source LinkViridian Therapeutics VRDN has announced detailed plans for a late-stage program on VRDN-003, its investigational subcutaneously (SC)-administered antibody, in patients with moderate-to-severe thyroid...
Source Link
Comments